Review Article

Advances in Antiviral Therapies for Chronic Hepatitis C: Improving Patient Outcomes

Ganesh Tapdiya

Department of Pharmacognosy, Shreeyash Institute of Pharmacy, Aurangabad, Maharashtra, India

Correspondence:
Dr. Ganesh Tapdiya, Department of Pharmacognosy, Shreeyash Institute of Pharmacy, Aurangabad - 431 001, Maharashtra, India.
E-mail: ganeshtapadiya@gmail.com

How to cite this article:
Tapdiya G. Advances in Antiviral Therapies for Chronic Hepatitis C: Improving Patient Outcomes. Innov Pharm Planet 2024;12(2):28-33.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 10-05-2024
Date of Revision: 20-05-2024
Date of Acceptance: 05-06-2024

ABSTRACT

Chronic hepatitis C (CHC) is a major global health issue, with millions of people affected worldwide. The advent of direct-acting antivirals (DAAs) has revolutionized the management of CHC, offering higher cure rates and improved patient outcomes. This review explores the latest antiviral treatments for CHC, emphasizing the mechanisms of action, efficacy, and patient outcomes. DAAs such as sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and ledipasvir/sofosbuvir have demonstrated significant improvements in cure rates (exceeding 95%) and patient satisfaction due to fewer side effects and shorter treatment durations. These therapies have reduced the burden of liver disease, including cirrhosis and hepatocellular carcinoma. However, challenges such as drug resistance, accessibility, and affordability remain. The future of hepatitis C management lies in the development of pan-genotypic therapies, effective vaccines, and global initiatives to improve treatment accessibility.

Keywords: Chronic hepatitis C, direct-acting antivirals, drug resistance, glecaprevir/pibrentasvir, hepatocellular carcinoma, pan-genotypic therapies, patient outcomes, sofosbuvir/velpatasvir, treatment accessibility, vaccine development, viral cure

Introduction

Chronic hepatitis C (CHC) is a significant global health challenge, affecting millions of individuals worldwide. The management of this condition has evolved dramatically over the past decade, primarily due to the advent of novel antiviral drugs known as direct-acting antivirals (DAAs). This review aims to explore the latest antiviral treatments for CHC and their impact on patient outcomes, emphasizing the importance of these advancements in improving cure rates and overall health.

Overview of CHC

CHC is caused by the hepatitis C virus (HCV), which can lead to severe liver disease, including cirrhosis and hepatocellular carcinoma (HCC). The virus has several genotypes, with genotype 1 being the most prevalent globally. Historically, treatment options were limited to interferon (IFN)-based therapies, which were often poorly tolerated and had variable efficacy. However, recent developments in antiviral therapy have transformed the landscape of CHC management, leading to higher cure rates and improved patient quality of life.[1]

Access this article online	
Website: https://innovationaljournals.com/index.php/ip	**e-ISSN:** 2348-7275
DOI: 10.31690/ipplanet.2024.v012i02.008	

Importance of Antiviral Treatments in Hepatitis C Management

The introduction of DAAs has revolutionized the treatment paradigm for CHC. These medications target specific steps in the HCV lifecycle, resulting in potent antiviral effects with minimal side effects compared to older therapies. DAAs have demonstrated cure rates exceeding 95% across various genotypes and patient populations, including those with advanced liver disease.[2] The significance of achieving a sustained virologic response (SVR) – defined as undetectable HCV RNA levels 12 weeks post-treatment – cannot be overstated, as it is associated with reduced morbidity and mortality related to liver disease.[3]

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution NonCommercial Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Purpose and Scope of the Review

This review will discuss the latest antiviral treatments for CHC, focusing on their mechanisms of action, efficacy, treatment regimens, and impact on patient outcomes. By synthesizing current literature from 2020 to 2021, this analysis aims to provide a comprehensive overview of how novel antiviral drugs have changed the management of CHC.

Latest Antiviral Treatments

DAAs

Sofosbuvir/velpatasvir (Epclusa)

This combination is effective against all HCV genotypes and is typically prescribed for patients without cirrhosis. Treatment duration is usually 12 weeks.

Glecaprevir/pibrentasvir (Mavyret)

Approved for all genotypes, Mavyret can be administered for as short as 8 weeks in certain patients without cirrhosis and has shown high SVR rates.

Ledipasvir/sofosbuvir (Harvoni)

This was one of the first single-tablet regimens approved for genotype 1 infections. It simplifies treatment adherence due to its once-daily dosing.[4]

Efficacy and safety

Clinical trials have consistently shown that DAAs are not only effective but also well-tolerated. Common side effects include fatigue and headaches, which are significantly milder than those associated with IFN therapy.

The rapid achievement of SVR with DAAs leads to improved liver health outcomes, including decreased risk of liver cancer and other complications associated with CHC.

Impact on patient outcomes

The shift from IFN -based therapies to all-oral DAA regimens has resulted in a paradigm shift in patient management. Patients report higher satisfaction levels due to fewer side effects and shorter treatment durations.[5]

Furthermore, achieving SVR translates into long-term health benefits, reducing healthcare costs associated with managing advanced liver disease complications.[1]

Epidemiology of CHC

Global and regional prevalence

CHC is a major global health issue, with an estimated 71 million people living with the infection worldwide. The prevalence varies significantly by region, with higher rates observed in areas such as East Asia, the Middle East, and North Africa. According to the World Health Organization, the highest prevalence rates are found in Egypt, where approximately 10% of the population is infected, largely due to historical practices in healthcare settings.[1,6] In contrast, Western Europe and North America report lower prevalence rates, often below 1%.[7]

The epidemiological landscape of CHC is influenced by various factors, including historical blood transfusion practices, injection drug use, and healthcare-associated infections. In regions where harm reduction strategies are implemented, such as needle exchange programs, there has been a notable decline in new infections. Conversely, areas lacking such interventions continue to see rising rates of chronic infections.[8]

Risk factors and transmission

The primary mode of transmission for HCV is through exposure to infected blood. Key risk factors include:

Injection drug use

Sharing needles or other drug paraphernalia is the most significant risk factor for HCV transmission.

Blood transfusions

Although screening has improved since the 1990s, transfusions from unscreened donors remain a risk in some regions.

Healthcare exposure

Unsafe medical practices, including inadequate sterilization of equipment and unsafe injections, contribute to transmission.

Vertical transmission

HCV can be transmitted from an infected mother to her child during childbirth.

Other potential risk factors include sexual contact with an infected person and sharing personal items that may have come into contact with blood, such as razors.[9]

Disease Progression and Complications

The progression of CHC can vary widely among individuals. After initial infection, approximately 15–45% of individuals will clear the virus spontaneously within 6 months; however, the remainder will develop chronic infection. Over time, chronic HCV infection can lead to significant liver damage, including.

Fibrosis

Scarring of liver tissue that can progress to cirrhosis.

Cirrhosis

Advanced scarring that can lead to liver failure and increases the risk of HCC.

HCC

A primary liver cancer that is a leading cause of cancer-related mortality in patients with CHC.

Regular monitoring and early intervention are crucial for managing disease progression and preventing complications associated with CHC.[10]

Pathophysiology of HCV Infection

HCV structure and replication cycle

HCV is a positive-sense single-stranded RNA virus belonging to the *Flaviviridae* family. Its genome is approximately 9.6 kb long and encodes a single polyprotein that is cleaved into structural and non-structural proteins essential for viral replication.[8]

The Replication Cycle of HCV Involves Several Key Stages

1. Viral entry: The virus binds to specific receptors on hepatocytes (liver cells), leading to endocytosis
2. Translation: The viral RNA is translated into a polyprotein at the rough endoplasmic reticulum
3. Replication: The viral genome undergoes replication through a negative-sense RNA intermediate
4. Assembly and release: New virions are assembled in a membrane-bound compartment and released through exocytosis[9]

This complex life cycle allows HCV to efficiently replicate within host cells while evading immune detection.

Immune Response to HCV

The immune response to HCV infection is multifaceted but often inadequate in clearing the virus. Initially, both innate and adaptive immune responses are activated; however, HCV employs various strategies to evade these defenses. For instance.

Interference with IFN signaling

HCV proteins can inhibit IFN signaling pathways, which are critical for antiviral responses.

Immune evasion

The virus can mutate rapidly, leading to antigenic variation that helps it escape recognition by neutralizing antibodies.[11] As a result, many individuals develop chronic infections characterized by persistent viral replication and ongoing liver inflammation.

Mechanisms of Liver Damage

Liver damage in CHC occurs through several mechanisms

Direct cytopathic effects

HCV replication within hepatocytes can lead to cell death.

Immune-mediated injury

The host's immune response contributes to liver inflammation and injury as it attempts to eliminate infected cells.

Fibrogenesis

Chronic inflammation stimulates fibrogenesis – the formation of fibrous tissue – which can progress to cirrhosis over time.

These mechanisms highlight the complex interplay between the virus and host immune responses that ultimately lead to significant liver pathology in CHC patients.[12]

Historical Perspective on Hepatitis C Treatments

Early treatment options: IFN and ribavirin

The treatment landscape for CHC has undergone significant changes since the identification of the HCV in the late 1980s. Initially, the standard treatment involved the use of IFN, a cytokine that modulates the immune response, often combined with ribavirin, an antiviral medication. IFN was administered either as a standard formulation or as pegylated IFN, which has a longer half-life, allowing for weekly dosing.

Ribavirin was used to enhance the antiviral effects of IFN, but its efficacy was limited, particularly in patients with HCV genotype 1, which is the most common genotype globally. The combination therapy typically required a treatment duration of 24–48 weeks, depending on the genotype and patient response. While some patients achieved a SVR, many experienced only partial responses or relapses after treatment cessation.[13]

Limitations and side effects of conventional treatments

Despite some successes, conventional treatments with IFN and ribavirin were fraught with limitations and side effects that significantly impacted patient adherence. Common side effects of IFN included flu-like symptoms, fatigue, depression, and autoimmune disorders. Ribavirin was associated with hemolytic anemia and other systemic effects. These adverse reactions led to premature discontinuation of therapy in approximately 10–20% of patients and necessitated dose modifications in an additional 20–30%.

Moreover, the efficacy of these treatments varied widely based on factors such as HCV genotype, patient age, and baseline liver function. The suboptimal cure rates and challenging side effect profiles underscored the need for more effective and tolerable therapies.

Transition to DAAs

The introduction of DAAs in the early 2010s marked a revolutionary shift in hepatitis C treatment. DAAs target specific steps in the HCV lifecycle, leading to more effective viral suppression with fewer side effects. Unlike IFN -based therapies, DAAs are administered orally and often in combination regimens that allow for shorter treatment durations – typically 8–12 weeks – with cure rates exceeding 95% across various genotypes.[14]

The transition from IFN-based therapy to DAAs has not only improved SVR rates but also enhanced patient quality of life by minimizing treatment-related morbidity. This paradigm shift has made hepatitis C treatment more accessible and acceptable to a broader range of patients, including those previously deemed unsuitable for therapy due to comorbidities or adverse reactions to older treatments.

Novel Antiviral Drugs for CHC

Introduction to DAAs

DAAs represent a new class of antiviral medications specifically designed to combat HCV infections. By targeting specific viral proteins involved in replication and assembly, DAAs provide a more focused approach compared to traditional therapies. This targeted action leads to higher efficacy rates and fewer side effects.

Classes of DAAs: NS3/4A Protease Inhibitors, NS5A Inhibitors, and NS5B Polymerase Inhibitors

DAAs can be categorized into several classes based on their mechanisms of action

1. NS3/4A protease inhibitors: These inhibit the HCV NS3/4A protease enzyme, which is crucial for processing viral proteins necessary for replication. Examples include glecaprevir and voxilaprevir
2. NS5A inhibitors: These target the NS5A protein involved in viral RNA replication and assembly. Notable examples include ledipasvir and ombitasvir
3. NS5B polymerase inhibitors: These inhibit the NS5B polymerase enzyme responsible for viral RNA synthesis. Sofosbuvir is a key drug in this category.

Key Drug Combinations

Several effective combinations of DAAs have been developed to enhance treatment efficacy.

Sofosbuvir/ledipasvir (Harvoni)

This combination is effective against HCV genotypes 1–4 and is taken once daily for 8–24 weeks.

Glecaprevir/pibrentasvir (Mavyret)

Approved for all genotypes, this regimen can be administered for as short as 8 weeks in certain patient populations without cirrhosis.

These combinations have demonstrated high SVR rates while minimizing treatment duration and complexity.[11]

Mechanism of Action of Novel Antivirals

The mechanisms by which DAAs exert their antiviral effects are distinct

Protease inhibitors block the cleavage of viral polyproteins into functional proteins necessary for viral replication.

NS5A inhibitors disrupt the replication process by preventing the formation of the replication complex.

Polymerase inhibitors interfere with viral RNA synthesis, effectively halting viral replication.

This multi-faceted approach not only enhances antiviral efficacy but also reduces the likelihood of resistance development compared to monotherapy with older agents.[15]

Clinical Efficacy of Novel Antiviral Therapies

SVR rates

Clinical trials have consistently shown that DAAs achieve SVR rates exceeding 95%, making them highly effective for treating CHC across various genotypes. The high SVR rates are particularly notable among previously difficult-to-treat populations, including those with cirrhosis or prior treatment failures.

Comparison of DAAs across different genotypes

DAAs have demonstrated high efficacy across all major HCV genotypes (1 through 6), significantly improving outcomes for patients infected with genotype 1, which historically had lower response rates to conventional therapies. The availability of pan-genotypic regimens such as glecaprevir/pibrentasvir has simplified treatment protocols further by eliminating the need for genotype testing before initiating therapy.[16]

Factors Influencing Treatment Success

Several factors influence the success of DAA therapy

Viral genotype
Certain genotypes may respond differently based on the specific DAA regimen used.

Baseline liver health
Patients with advanced liver disease may require longer treatment durations or different combinations.

Adherence to therapy
Maintaining strict adherence to prescribed regimens is crucial for achieving SVR.

Safety Profile and Side Effects

Common side effects of DAAs

DAAs have transformed the treatment of CHC by offering higher efficacy and fewer side effects compared to earlier therapies. Common side effects associated with DAAs include.

Fatigue

Reported in approximately 14% of patients.[17]

Headache

Occurring in about 13% of patients.[18]

Nausea

Affects around 10% of patients, often transient.[18]

Diarrhea

Another common side effect, though less frequent than fatigue and headache.

Insomnia and irritability

These can also occur but are generally less common.[17]

Most side effects are mild-to-moderate and tend to resolve after treatment completion.

Adverse Events and Management

While DAAs are generally well-tolerated, some adverse events can occur. Serious adverse events are rare, with studies indicating that DAAs do not significantly increase the risk of severe complications such as liver failure or multiple organ failure compared to non-DAA treatments. The management of side effects typically involves supportive care and monitoring. For instance:

Fatigue and headache can often be managed with over-the-counter analgesics.

Nausea may be alleviated with antiemetic medications.

In cases where side effects are persistent or severe, healthcare providers may consider dose adjustments or switching to alternative therapies.

Long-term safety considerations

Long-term safety data for DAAs continue to emerge, but current evidence suggests that they have a favorable safety profile. Concerns regarding potential reactivation of hepatitis B virus in co-infected individuals have been noted, necessitating careful screening and monitoring.[19] Overall, the incidence of serious adverse events remains low, reinforcing the notion that DAAs are a safe option for most patients.

Impact on Patient Outcomes

Improvements in quality of life and liver function

The introduction of DAAs has led to significant improvements in both quality of life and liver function among patients with CHC. Achieving a SVR not only indicates viral clearance but is also associated with improved liver health, reduced fatigue, and enhanced overall well-being. Many patients report a return to normal activities post-treatment due to the alleviation of symptoms related to chronic infection.

Reduction in HCV-related mortality and morbidity

DAAs have demonstrated a marked reduction in HCV-related morbidity and mortality. Studies indicate that achieving SVR significantly lowers the risk of developing cirrhosis, liver cancer, and other complications associated with CHC. The long-term benefits of viral eradication include decreased healthcare costs related to managing advanced liver disease.

Economic impact and cost-effectiveness of novel therapies

The economic implications of DAAs are significant. While the upfront costs of these therapies can be high, studies have shown that they are cost-effective when considering the long-term savings associated with reduced disease progression and complications. The cost-effectiveness is particularly evident when evaluating the overall healthcare expenditures related to CHC management versus the benefits gained from curing the infection.

Challenges and Limitations of Novel Antiviral Therapy

Drug resistance and relapse

Despite their high efficacy rates, there is a potential risk for drug resistance and relapse in some patients, particularly those with prior treatment failures or specific viral genotypes. Continuous monitoring for virologic response during and after treatment is essential to manage these risks effectively.

Access and affordability

Access to DAAs remains a critical challenge globally. While these therapies are available in many high-income countries, barriers such as high costs, limited availability in low-income regions, and restrictive healthcare policies hinder widespread access. Efforts to improve affordability through generic formulations and public health initiatives are ongoing but need further expansion.[20]

Challenges in Treating Special Populations

Certain populations present unique challenges in hepatitis C management

Co-infection with HIV

Patients co-infected with HIV may experience different responses to treatment and require careful management due to potential drug interactions.

Advanced liver disease

Patients with decompensated cirrhosis may face increased risks during treatment, necessitating specialized care approaches.

Addressing these challenges is crucial for optimizing outcomes in all patient populations.

Future Directions in Hepatitis C Management

Development of pan-genotypic therapies

Future research is focused on developing pan-genotypic therapies that can effectively treat all HCV genotypes without the need for prior genotype testing. This approach simplifies treatment protocols and increases accessibility for diverse patient populations.

Role of vaccination in hepatitis C prevention

The development of an effective vaccine against hepatitis C remains a priority in public health initiatives. A successful vaccine could significantly reduce the incidence of new infections and contribute to global efforts aimed at eliminating hepatitis C as a public health threat.

Addressing barriers to access and global treatment initiatives

Efforts must continue to address barriers related to access and affordability. Global initiatives aimed at increasing awareness, improving healthcare infrastructure, and ensuring equitable access to treatment are essential for achieving broader public health goals.

Conclusion

The development of novel antiviral drugs has transformed the management of CHC, offering high cure rates and improved tolerability. DAAs have significantly enhanced patient outcomes, reducing the global burden of liver disease. Despite their success, challenges related to access, affordability, and treatment for special populations remain.

Looking ahead, advancements in pan-genotypic therapies, vaccination strategies, and addressing systemic barriers to care hold great promise. Ongoing research and collaboration among healthcare providers, policymakers, and advocacy groups are crucial to ensuring equitable access and continued progress in hepatitis C management worldwide.

References

1. Velosa J, Serejo F, Ramalho F, Marinho R, Rodrigues B, Baldaia C, *et al*. A practical guide for antiviral therapy of chronic Hepatitis C. GE Portuguese J Gastroenterol 2014;21:221-30.
2. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: A systematic review. JAMA 2014;312:631-40.
3. Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. Hemodial Int 2018;22: S8-21.
4. Marks K, Naggie S. Management of hepatitis C in 2019. JAMA 2019;322:355-6.
5. Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, *et al*. Hepatitis C treatment: Where are we now? Int J Gen Med 2017;10:39-52.
6. Li HC, Yang CH, Lo SY. Cellular factors involved in the hepatitis C virus life cycle. World J Gastroenterol 2021;27:4555.
7. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
8. Tabata K, Neufeldt CJ, Bartenschlager R. Hepatitis C virus replication. Cold Spring Harb Perspect Med 2020;10:a037093.
9. Gerold G, Pietschmann T. The HCV life cycle: *In vitro* tissue culture systems and therapeutic targets. Dig Dis 2014;32:525-37.
10. Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV life cycle with a special focus on current and possible future antiviral targets. Viruses 2019;11:30.
11. Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: Life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016;22:826-32.
12. Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle-An update. J Hepatol 2014;61:S3-13.
13. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: Efficacy, side effects, and complications. Gut 2006;55:1350-9.
14. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2016;66:153-94.
15. Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of chronic hepatitis C: Efficacy, side effects and complications. Visc Med 2019;35:161-70.
16. Panel AI. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477.
17. Lei PK, Liu Z, Ung CO, Hu H. Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: A systematic review and meta-analysis. BMC Gastroenterol 2024;24:331.
18. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-9.
19. McGlynn EA, Adams JL, Kramer J, Sahota AK, Silverberg MJ, Shenkman E, *et al*. Assessing the safety of direct-acting antiviral agents for hepatitis C. JAMA Netw Open 2019;2:e194765.
20. Ali AA, Elbedewy RM, Sherief AF, Ashraf O, Mousa HA. Potential side effects of directly acting antivirals (DAAs) after one and three months of treatment among Egyptian elderly patients. Egypt J Geriatr Gerontol 2020;7:12-8.